Extended-spectrum β-lactamase (ESBL) Produced by <I>Escherichia coli</I> and <I>Klebsiella pneumoniae</I> Isolated from Teikyou University Hospital The First Report

• KAWAKAMI Sayoko

  Department of Central Clinical Laboratory, Teikyo University School of Medicine

• ONO Yasuo

  Department of Microbiology&Immunology, Teikyo University School of Medicine

• YAMAMOTO Miwa

  Department of Central Clinical Laboratory, Teikyo University School of Medicine

• MATUMURA Mituru

  Department of Central Clinical Laboratory, Teikyo University School of Medicine

• OKAMOTO Ryoich

  Teikyo University School of Medicine and Department of Microbiology Kitasato University School of Medicine

• INOUE Matsuhisa

  Teikyo University School of Medicine and Department of Microbiology Kitasato University School of Medicine

• MIYAZAWA Yukihisa

  Department of Central Clinical Laboratory, Teikyo University School of Medicine

Bibliographic Information

Other Title

• 帝京大学医学部附属病院におけるcefotaxime耐性の<I>Escherichia coli</I>と<I>Klebsiella pneumoniae</I>の検出状況第1報
• 帝京大学医学部附属病院におけるcefotaxime耐性のEscherichia coliとKlebsiella pneumoniaeの検出状況(第1報)
• テイキョウ ダイガク イガクブ フゾク ビョウイン ニ オケル cefotaxime タイセイ ノ Escherichia coli ト Klebsiella pneumoniae ノ ケンシュツ ジョウキョウ ダイ1ポウ
• Extended-spectrum ^|^beta;-lactamase (ESBL) Produced by Escherichia coli and Klebsiella pneumoniae Isolated from Teikyou University Hospital The First Report

Abstract

We studied the cefotaxime (CTX)-resistant (MIC≥32 μg/ml) clinical isolates of E. coli and K. pneumoniae in Teikyo University Hospital from 1990 to 1996. The incidence of CTX-resistant isolates was 0.4% (6/1, 282) in E. coli and 0.6% (7/1, 044) in K. pneumoniae, in 1990. In 1995, the incidence of CTX-resistance increased to 1.7% (50/2, 910) in E. coli (p=0.0013) and 7.2% (144/1, 996) in K. pneumoniae (p<0.0001).<BR>These species have been detected in the stool (86 isolates), urine (59 isolates), sputum (15 isolates), pus (15 isolates), throat (10 isolates) and others (12 isolates) in 1995.<BR>MIC₅₀ of ampicillin (ABPC), ABPC with clavlanic acid (CVA) 5μg/ml, piperacillin (PIPC), PIPC with CVA 5μg/ml, ceftazidime, CTX, ceftizoxime, cefpodoxime, cefepime, aztreonam, cefmetazole, latamoxef, and imipenem used against 33 isolates (11 isolates of E. coli, 22 isolates of K. pneumoniae), which were detected in 1996-1997, was >512μg/ml, 8μg/ml, >512μg/ml, 8μg/ml, 4μg/ml, >512μg/ml, 16μg/ml, >512μg/ml, 256μg/ml, 32μg/ml, 2μg/ml, 0.25μg/ml and 0.25μg/ml, respectively.<BR>This susceptibility pattern were very similar to the Toho-1 type β-lactamases producing strains.

Journal

• Kansenshogaku Zasshi

  Kansenshogaku Zasshi 73 (11), 1110-1115, 1999

  The Japanese Association for Infectious Diseases

Keywords

• Escherichia coli
• Klebsiella pneumonfae
• Extended-Spectrum β-Lactamase (ESBL)
• plasmid

Details

• CRID: 1390001205050929664
• NII Article ID: 130004112683
• NII Article ID: 10008327279
• NII Article ID: 10008716763
• NII Book ID: AN00047715
• DOI: 10.11150/kansenshogakuzasshi1970.73.1110
• ISSN: 1884569X
• ISSN: 03875911
• NDL BIB ID: 4925188
• PubMed: 10624090
• Web Site: https://ndlsearch.ndl.go.jp/books/R000000004-I4925188
• Web Site: https://search.jamas.or.jp/link/ui/2000071316
• Data Source:
  • JaLC
  • NDL
  • Crossref
  • PubMed
  • CiNii Articles
• Abstract License Flag: Disallowed